Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors
Turnstone’s innovative approach with TIDAL-01 focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) to overcome the...


















